FDA Okays Jaw-Jiggling Gadgets to Diagnose Sleep Apnea
Published Date: 4/22/2026
Rule
Summary
The FDA is officially putting sleep apnea testing devices that track jaw movement into a safer, easier-to-manage category called Class II. This change helps make sure the devices work well and are safe, while also making it simpler for new, helpful devices to reach patients faster. The new rules took effect on April 22, 2026, and could save companies time and money by cutting down on red tape.
Analyzed Economic Effects
5 provisions identified: 3 benefits, 2 costs, 0 mixed.
Reclassified to Class II — Faster Access
The FDA classified devices that test for sleep apnea by measuring jaw (mandibular) movement into Class II with special controls, effective April 22, 2026 (classification applicable January 7, 2022). FDA says this Class II classification will provide reasonable assurance of safety and help enhance patients' access to beneficial innovative devices by reducing regulatory burdens.
New Predicate Pathway for Device Makers
Because FDA classified the mandibular-movement sleep apnea device via the De Novo process, that device type can serve as a predicate for future devices so other sponsors can use the less-burdensome 510(k) pathway instead of a De Novo request or premarket approval. This change can shorten time and reduce regulatory hurdles for companies developing similar devices.
510(k) Premarket Notification Required
FDA states that devices for sleep apnea testing based on mandibular movement are subject to premarket notification under section 510(k) of the FD&C Act (i.e., manufacturers must submit a 510(k) unless FDA later exempts the device type).
Special Controls Require Safety Data and Labeling
FDA established special controls requiring clinical data representative of the intended-use population, biocompatibility of patient-contacting components, electromagnetic and electrical safety testing, comprehensive software verification and validation (including hazard analysis and algorithm description), and specific labeling statements about device outputs and limits.
Devices Designated Prescription-Only
FDA states that devices for sleep apnea testing based on mandibular movement are prescription devices (prescription use only) and are not intended to substitute for full polysomnography nor to be used as apnea monitors.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He didn’t respond to the FDA’s warning, so the ban started on May 15, 2026. If he wants to end the ban early, he can apply anytime, but must follow special rules to keep his info private.
2026-09533 — Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information
The FDA wants your help to improve tests that spot kidney damage caused by medicines. They’re asking researchers, doctors, and companies to share data by July 13, 2026, so they can make these kidney safety markers better and faster. This could lead to safer drugs and smarter health checks, benefiting patients and the medical community alike.
2026-09508 — Azodicarbonamide (ADA); Request for Information
The FDA is asking for info about azodicarbonamide (ADA), a chemical used in some foods and food packaging, to check if it’s still safe. Food makers, scientists, and anyone with data should share what they know by July 13, 2026. This review could lead to changes in how ADA is used, affecting food companies and possibly costs down the line.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This update affects drug makers and helps keep medicine safe by improving how side effects are tracked. You’ve got until July 13, 2026, to share your comments—no cost to join, just your voice!
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If renewed, the company can keep marketing them this way, with the comment period starting May 13, 2026.
2026-09507 — Butylated Hydroxytoluene (BHT); Request for Information
The FDA wants to know more about how butylated hydroxytoluene (BHT), a chemical used in food and food packaging, is being used and if it’s still safe. They’re asking companies, scientists, and the public to share any info by July 13, 2026. This could lead to changes in rules that affect food makers and might impact what’s allowed in your snacks and packaging.
Previous / Next Documents
Previous: 2026-07861 — Medical Devices; Ophthalmic Devices; Classification of the Digital Therapy Device for Amblyopia
The FDA is officially classifying the digital therapy device for amblyopia (lazy eye) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool, innovative treatment faster and safer, starting April 22, 2026. Device makers will benefit from simpler rules, saving time and money while keeping safety top-notch.
Next: 2026-07863 — Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Setmelanotide Eligibility Gene Variant Detection System
The FDA is officially putting the Setmelanotide Eligibility Gene Variant Detection System into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this cool new technology. The new rules took effect on April 22, 2026, but the classification has been in place since January 21, 2022, meaning less red tape and smoother approvals for makers and users.